Nanoparticle Composition for Low-Toxicity Anionic Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery systems, particularly those using cationic lipids and polycationic polymers, face issues such as cytotoxicity, low stability, and inefficient intracellular delivery of anionic drugs, making them unsuitable for safe and effective in vivo use.
Innovation Solution
A composition comprising a lipid with a specific structure and an amphiphilic block copolymer forms a complex with anionic drugs, encapsulating them in nanoparticles for targeted delivery, especially to the lung, enhancing stability and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipid or polycationic polymer is used to form complex with anionic drug, then intracellular delivery is improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the carrier by using modified cholesterol derivatives with specific molecular structures (Formula 1-4) instead of traditional cationic lipids or polycationic polymers. These modified structures provide drug complexation capability without the harmful multivalent cationic charges, thus reducing cytotoxicity while maintaining delivery efficiency.
Solution Approach 2:
The patent creates a composite nanoparticle system comprising modified cholesterol derivatives, amphiphilic block copolymers, and anionic drugs. This composite structure combines the advantages of different materials to achieve effective drug delivery without the cytotoxicity problems of individual cationic components.
2Productivity
If nucleic acid-cationic lipid complex is formed, then intracellular delivery is enhanced, but stability in blood decreases
Solution Approach 1:
The patent modifies the molecular structure of cholesterol derivatives to create carriers that form stable complexes with nucleic acids in blood circulation while maintaining intracellular delivery capability. The specific structural parameters (Formula 1-4) are optimized to balance stability and delivery efficiency.
3Productivity
If ionic liposome is used for nucleic acid delivery, then delivery capability is improved, but synthesis complexity and cytotoxicity increase
Solution Approach 1:
The patent extracts and utilizes the advantageous properties of cholesterol (biocompatibility, membrane interaction) while eliminating the problematic aspects of complex ionic liposome formulations. The modified cholesterol derivatives provide simplified synthesis routes compared to traditional multi-component ionic liposomes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition allows for efficient and stable delivery of drugs, including nucleic acids and polypeptides, to the lung, with improved safety and reduced toxicity, facilitating rapid preparation and administration without complex processes.
Implementation Method 1
stabilizes anionic drug by forming a complex through electrostatic interaction with the anionic drug
Implementation Method 2
amphiphilic block copolymer and lipid with a specific structure capable of easily forming a complex with anionic drug, and can easily form drug-containing nanoparticle
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention relates to a nanoparticle composition for drug delivery and, more specifically, to a composition for drug delivery, wherein the composition comprises an amphiphilic block copolymer and a lipid with a specific structure that can easily form complexes with anionic drugs, whereby the composition can easily form drug-containing nanoparticles and thus is useful for drug delivery, especially for targeted delivery of drugs to the lungs.